A Two Part First-in-human Phase I Study (With Expanded Cohorts) With the Antibody-drug Conjugate SYD985 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Two Part First-in-human Phase I Study (With Expanded Cohorts) With the Antibody-drug Conjugate SYD985 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs SYD 985 (Primary)
  • Indications Advanced breast cancer; Endometrial cancer; Gastric cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Synthon
  • Most Recent Events

    • 13 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Apr 2017.
    • 18 May 2016 Results from dose finding part of the study published in the Synthon Pharmaceuticals media release.
    • 18 May 2016 According to a Synthon Pharmaceuticals media release, second part of this study which will evaluate 48 additional heavily pre-treated patients with HER2-positive breast cancer has been initiated. Data from this cohort will enable Synthon to design the first pivotal trial with SYD985 as suggested by several national regulatory authorities and subject to an ongoing EMA scientific advice request regarding the most optimal development pathway.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top